Compare AU
Compare HQUS vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are HQUS and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
HQUS | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 63 |
Median incremental investment | $856.94 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $847.02 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Key Summary
HQUS | DRUG | |
|---|---|---|
Strategy | HQUS.AX was created on 2024-07-10 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. HQUS.AX aims to track the performance of the S&P 500 Equal Weight AUD Hedged Index NTR. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | BetaShares S&P 500 Equal Weight Currency Hedged ETF (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.29 % | 0.57 % |
Key Summary
HQUS | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | S&P 500 Equal Weight AUD Hedged Index - AUD - Benchmark TR Net Hedged | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.29 % | 0.57 % |
Price | $44.58 | $8.12 |
Size | N/A | $191.120 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | - % | 1.90 % |
Market | ASX | ASX |
First listed date | 11/07/2024 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
HQUS | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 63 |
Median incremental investment | $856.94 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $847.02 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
HQUS | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
HQUS | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |